# Hunan Nucien Pharmaceutical Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/hunan-nucien-pharmaceutical-co

- Industry: Pharmaceuticals
- Headquarters: Guangzhou, China
- Website: www.nucien.com
- Latest round: Series A (Sep 1, 2016)
- Investors on record: 2

## About

Established in 2006 and based in Changsha, China, Hunan Nucien Pharmaceutical Co., Ltd. is a pharmaceutical company that focuses on development, production and marketing of drugs, providing anti-infective products, cardiovascular products, urinary tract infection specialist products, digestive products antipyretic analgesics and anti-allergic products. The company is the director unit of Guangdong Biomedical Innovation and Technology Association and also acquired the China Patent Silver Award. In October 2017, the company closed a strategic investment from new investor Xiangjiang Industrial Investment. In March 2020, Hunan Nucien Pharmaceutical Co., Ltd. was listed on Shanghai Stock Exchange.

Nucien focuses on the development of novel drugs such as anti-influenza viruses and cardiovascular drugs. Its main products are Paramivir, Gefitinib, Ezetimibe, Ciprofloxacin, Ciprofloxacin Hydrochloride and Simvastatin. The drugs can be used in the fields of anti-infective, cardio-cerebral vascular, anti-tumour and other drugs. The company also provides users with medication guidance and health counselling services.

The company generates revenue by developing and offering novel drugs such as anti-influenza viruses and cardiovascular drugs.

## Funding rounds

- Series A, Sep 1, 2016 — CDH Investments, Xiangjiang Liyuan Investment

## Investors

- CDH Investments (https://capitalatlas.ai/funds/cdh-investments) — Series A
- Xiangjiang Liyuan Investment (https://capitalatlas.ai/funds/xiangjiang-liyuan-investment) — Series A